After gaining an impressive $63 million in the first tranche of its third round in January, Malvern, PA-based Ception upped the ante by gaining an additional $14.7 in its second trancheÂ in May, bringing the grand total to $77 million in its third round. Participants included Essex Woodlands Health Ventures, Third Point and Greenlight Capital. Ceptionâ€™s pipeline includes a late-stage biologic agent in clinical development for multiple inflammatory conditions, a small molecule anti-TNF program and other discovery programs. The company plans to use the money to advance its lead compound as well as support development of earlier-stage drug targets.
Ception Therapeutics pockets $63M in third round. Report